Lilly's tirzepatide manufacturing bet, begun in 2020, grows past $50 billion

Eli Lilly began its manufacturing buildout in 2020 on the strength of research results for tirzepatide, the molecule sold as Mounjaro and Zepbound, years before either medicine was approved ^[1]. The company has described the spending as a decision made "at risk" so that it could supply the market once approvals arrived — Mounjaro in 2022 and Zepbound in 2023 ^[1].

The company's published manufacturing totals are all counted from that 2020 starting point ^[1][2].

The spending so far

On May 24, 2024, Lilly said it had more than doubled its investment in a Lebanon, Indiana, site with a new $5.3 billion commitment, raising the total for that site from $3.7 billion to $9 billion ^[1]. The plant is being built to make active pharmaceutical ingredients (API) for Zepbound and Mounjaro injection so that, in the company's words, "more adults with chronic diseases like obesity and type 2 diabetes may benefit from these important treatments" ^[1].

At the time, Lilly said it had committed more than $16 billion since 2020 to develop new sites in the U.S. and Europe, including Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and Alzey, Germany. A further $1.2 billion went to updating existing Indianapolis facilities, and the company acquired an injectable manufacturing plant in Pleasant Prairie, Wisconsin, from Nexus Pharmaceuticals. Lilly put the combined total at more than $18 billion ^[1].

"Today's announcement tops the largest manufacturing investment in our company's history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in U.S. history," chair and CEO David A. Ricks said ^[1].

On February 26, 2025, Lilly said it planned four more U.S. manufacturing sites, bringing its total U.S. capital expansion commitments to more than $50 billion since 2020 ^[2]. Three of the new sites are intended for API production, including small-molecule chemical synthesis; the fourth would make injectable therapies ^[2]. Lilly said the sites could create more than 3,000 company jobs and nearly 10,000 construction jobs ^[2].

The two releases count differently. The $18 billion figure from May 2024 covered sites in the U.S. and Europe ^[1]. The February 2025 release counts U.S. commitments only and says the company's domestic commitments from 2020 through 2024 alone totaled $23 billion ^[2].

Why it matters for patients

Mounjaro and Zepbound are both tirzepatide, and Lilly has said the 2020 decision was made specifically to have capacity ready for them ^[1]. How much of a medicine a company can produce affects how reliably it reaches pharmacies, though neither release states how much tirzepatide Lilly can currently make or whether supply is keeping up with demand. Those figures have not been disclosed in these releases.

Most of the new capacity is not available yet. Lilly broke ground at the Lebanon site in 2023 and said it expects to begin making medicines there toward the end of 2026, with operations scaling up through 2028 ^[1]. The four sites announced in February 2025 are not yet located or built; Lilly said it expects those facilities to begin making medicines for patients within five years ^[2].

Neither release addresses pricing, insurance coverage or whether the added capacity will change what patients pay. The releases also do not say how the investment is financed or what it means for Lilly's other medicines beyond the pipeline mentioned ^[1][2].

What happens next

Lilly said it expects to announce the locations of all four future U.S. sites in 2025, and it set a March 12, 2025 deadline for states to express interest in hosting them ^[2]. At the Lebanon site, the company's stated timetable is production starting around the end of 2026 and scaling through 2028 ^[1]. The releases do not give a date by which the four newer sites would be finished beyond the five-year production target ^[2].